Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-27T19:58:23.789Z Has data issue: false hasContentIssue false
  • English
  • Français

Selecting a Serotonin Reuptake Inhibitor for Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  07 November 2014

Alison Kelly
Get access Rights & Permissions [Opens in a new window]

Abstract

Although considered rare and intractable until relatively recently, obsessive-compulsive disorder (OCD) is now recognized as a common condition that can be treated. Clomipramine initially dominated the treatment of OCD, but the introduction of the selective serotonin reup-take inhibitors (SSRIs) now allows OCD to be treated without the unpleasant adverse effects associated with the high doses of clomipramine necessary in OCD. Double-blind, placebo-controlled, and active treatment comparison trials showing the efficacy of fluvoxamine and fluoxetine in particular now provide good reasons to consider SSRIs as first-line therapy for OCD.

Type
Feature Articles
Information
CNS Spectrums , Volume 1 , Issue 2 , November 1996 , pp. 32 - 38
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Black, A. The natural history of obsessional neurosis. In: Beech, HR, ed. Obsessional States. London: Methuen & Co; 1974.Google Scholar
2.Karno, M, Golding, J, Sorenson, S, Burnham, MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094–1099.CrossRefGoogle ScholarPubMed
3.Hollander, E, Fay, M, Cohen, B, et al. , Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioural findings. Am J Psychiatry. 1988;145:1015–1017.Google Scholar
4.Zohar, J, Meuller, EA, Insel, TR, et al. , Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry. 1987;44:946–951.CrossRefGoogle ScholarPubMed
5.Bastani, B, Nash, JF, Meltzer, HY. Prolactin and cortisol responses to MK212, a serotonin agonist in obsessive compulsive disorder. Arch Gen Psychiatry. 1990;47:833–837.CrossRefGoogle ScholarPubMed
6.Insel, TR, Mueller, EA, Alterman, I. Pathogenesis of obsessive compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985;20:1174–1188.CrossRefGoogle Scholar
7.Thoren, P, Asberg, M, Cronholm, B, Jornestedt, L, Traskman, L. Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Arch Gen Psychiatry. 1980;37: 1281–1285.CrossRefGoogle ScholarPubMed
8.Ananth, J, Pecknold, JC, van den Steen, N, Engelsmann F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol. 1981;5:257–262.CrossRefGoogle ScholarPubMed
9.Volavka, J, Neziroglu, F. Yarayura-Tobias, JA. Clomipramine and imipramine in obsessive compulsive disorder. Psychiat Res. 1985;14:83–91.CrossRefGoogle ScholarPubMed
10.Leonard, HL, Swedo, SE, Rapoport, JL, et al. , Treatment of obsessive compulsive disorder with clomipramine and desipramine in children and adolescents. Arch Gen Psychiatry. 1989;46:1088–1092.CrossRefGoogle ScholarPubMed
11.Ananth, J, Pecknold, JC, Van Der Steen, N, et al. , Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacoi. 1981;5: 257–262.CrossRefGoogle ScholarPubMed
12.DeVeaugh-Geiss, J, Landau, P, Katz, R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull. 1989;25:36–40.Google ScholarPubMed
13.Jenike, MA, Baer, L, Summergrad, P, Weilburg, JB, Holland, A, Seymour, R. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am J Psychiatry. 1989;146:1328–1330.Google ScholarPubMed
14.Katz, RJ, Landau, P, DeVeaugh-Geiss, J, Hakkarainen, H. Therapeutic effects of anafranil in obsessive compulsive disorder. Recent clinical findings. Prog Clin Biol Res. 1990:361:489–493.Google ScholarPubMed
15.Greist, JH, Jefferson, JW, Rosenfeld, R. Gutzmann, LD, March, JS, Barklage, NE. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. J CM Psychiatry. 1990;51:292–297.Google ScholarPubMed
16.The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:730–738.CrossRefGoogle Scholar
17.Pato, MT, Pigott, TA, Hill, JL, Grover, GN, Bernstein, S, Murphy, DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry. 1991; 148:127–129.Google ScholarPubMed
18.Hewlett, WA, Vinogradov, S, Agras, WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J CM Psychopharmacol. 1992:12:420–430.Google ScholarPubMed
19.Vallejo, J, Olivares, J, Marcos, T, Bulbena, A, Menchon, JM. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry. 1992;161:665–670.CrossRefGoogle ScholarPubMed
20.Perse, TL, Greist, JH, Jefferson, JW, Rosenfeld, R, Dar, R. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry. 1987;144:1543–1548.Google ScholarPubMed
21.Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR, Charney, DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36–44.CrossRefGoogle ScholarPubMed
22.Jenike, MA, Hyman, S, Baer, L, et al. , A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry. 1990;48:1415–1416.Google Scholar
23.Mallaya, GK, White, K, Waternaux, G, Quay, S. Short- and long-term treatment of obsessive compulsive disorder. Ann CM Psychiatry. 1992;4:77–80.CrossRefGoogle Scholar
24.Greist, JH, Jenike, MA, Robinson, D, Rasmussen, SA. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trial. Eur J Clin Res. 1995;7:195–204.Google Scholar
25.Goodman, WK, Kozak, MJ, Liebowitz, M, White, KL. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol In press.Google Scholar
26.Smeraldi, E, Erzegovesi, S, Bianchi, I, Pasquali, L, Cocchi, S, Ronchi, P. Fluvoxamine vs clomipramine treatment in obsessive compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry. 1992;8:63–65.Google Scholar
27.Freeman, CP, Trimble, MR, Deakin, JF, Stokes, TM, Ashford, JJ. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel-group comparison. J Clin Psychiatry. 1994;55:301–305.Google ScholarPubMed
28.Yargic, LI, Enderer, M, Imre, H, Sen, D, Yazici, O. A randomized, single-blind comparison of clomipramine and fluvoxamine in OCD patients. Nowpsikiyatr Ars. 1995;32:70–75.Google Scholar
29.Koran, LM, McElroy, SL, Davidson, JRT, Rasmussen, SA, Hollander, E, Jenike, MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol. In press.Google Scholar
30.Goodman, WK, Price, LH, Delgado, PL, et al. , Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990;48:483–484.Google Scholar
31.Pigott, TA, Pato, MT, Bernstein, SE, et al. , Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioural and biological results. Arch Gen Psychiatry. 1990;47:926–932.CrossRefGoogle ScholarPubMed
32.Ananth, J, Elmishad, A, Wohl, M. Clomipramine vs fluoxetine in obsessive compulsive disorder: an uncontrolled study. Adv Ther. 1993;10:288–292.Google Scholar
33.Montgomery, SA, Mclntyre, A, Osterheider, M, et al. , for The Lilly European OCD Study Group. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-IIl-R obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1993;3:143–152.CrossRefGoogle ScholarPubMed
34.Tollefson, GD, Rampey, AH, Potvin, JH, et al. , A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatry. 1994;51:559–567.CrossRefGoogle ScholarPubMed
35.Chouinard, G, Goodman, W, Greist, J, et al. , Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990;26:279–284.Google ScholarPubMed
36.Greist, JH, Jefferson, JW, Kobak, KA, et al. , A 1-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:57–65.CrossRefGoogle Scholar
37.Jenike, MA, Baer, L, Summergrad, P, Minichiello, WE, Holland, A, Seymour, R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry. 1990;147:923–928.Google ScholarPubMed
38.Kaye, NS, Dancu, C. Paroxetine and obsessive-compulsive disorder. Am J Psychiatry. 1994;151:1523.Google ScholarPubMed
39.Goodman, WK, Steiner, M, Bushnell, W, et al. , Efficacy of fixed doses of paroxetine in the treatment of obsessive-compulsive disorder: a randomized double-blind trial. J Clin Psychopharmacology. In press.Google Scholar
40.Hollander, E, Wong, CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry. 1995;56(suppl 4):3–6.Google ScholarPubMed
41.Phillips, KA, McElroy, SL, Hudson, JI, Pope, HG Jr.Body dysmorphic disorder: an obsessive-compulsive spectrum dis-order, a form of affective spectrum disorder, or both? J Clin Psychiatry. 1995;56 (suppl 4):41–52.Google Scholar
42.Hollander, E, Wong, CM. Body dysmorphic disorder, patho-logical gambling, and sexual compulsions. J CM Psychiatry. 1995;56;(suppl 4):7–13.Google Scholar
43.Flament, MF, Whitaker, A, Rapaport, JL. Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry. 1988;27:764–771.CrossRefGoogle ScholarPubMed
44.Apter, A, Ratzioni, G, King, R. Fluvoxamine open label treatment of adolescent in-patients with obsessive compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry. 1994;33:342–348.CrossRefGoogle ScholarPubMed
45.Riddle, MA, Hardin, MT, King, R, Scahill, L, Woolston, JL. Fluoxetine treatment of obsessions and compulsions in patients with Tourette's syndrome. Am J Psychiatry. 1988;145:1173–1174.Google ScholarPubMed
46.Dominguez, RA, Mestre, SM. Management of treatment-refractory obsessive compulsive disorder patients. J Clin Psychiatry. 1994;55: (suppl 10):86–92.Google ScholarPubMed
47.Van Balkom, AJLM, Van Oppen, P, Vermeulen, AWA, Van Dyck, R, Nauta, MCE, Vorst, HCM. A meta-analysis on the treatment of obsessive compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy. Clin Psychol Rev. 1994;14:359–381.CrossRefGoogle Scholar
48.Stein, DJ, Spadaccini, E, Hollander, E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:11–18.CrossRefGoogle ScholarPubMed